Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It
- Novartis Canada will not seek reimbursement for Vanrafia (atrasentan) in IgA nephropathy, a spokesperson confirmed, citing limited likelihood of securing it under the current access environment. Without reimbursement the drug does not reach Canadian pharmacies, hospital formularies or public and private plans.
- Health Canada approved Vanrafia on 13 July 2026 for proteinuria reduction in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio of 1.5 g/g or above, according to Novartis Canada. The product monograph is dated 2 July 2026.
- The authorisation rests on a prespecified interim analysis at Week 36 of the Phase III ALIGN study, in adults with biopsy-proven primary IgAN, eGFR of 30 mL/min/1.73 m2 or above and total urine protein of 1 g/day or more on maximally tolerated RAS inhibitor therapy. The release describes no kidney function outcome.
- Canadian reimbursement runs sequentially: the Patented Medicine Prices Review Board sets a ceiling against OECD comparators, Canada’s Drug Agency recommends, the pan-Canadian Pharmaceutical Alliance negotiates, then provinces decide on listing. Agency data reported alongside the decision put fewer than 50% of Health Canada approvals as reaching that review at all.
Access read
The reporting frames this as a country driving a company away. Read the approval instead. Health Canada authorised on a Week 36 interim analysis of a surrogate. Novartis cleared market authorisation on that package, then declined to take the same package into pricing.
- Authorisation and reimbursement are different evidentiary bars, and the gap is the story. Proteinuria at Week 36 satisfies a regulator asking whether the drug works. It is thin material for four bodies in sequence asking what it is worth. Nothing failed here, because nothing was submitted.
- This is asset triage, not market exit. The same release states Novartis Canada employs roughly 500 people and invests over $36 million in Canadian R&D each year. The infrastructure stays. One dossier in one indication was declined. Price the decision per asset, not per country.
- The base rate already pointed here. With fewer than 50% of Health Canada approvals advancing to reimbursement review, non-submission is a routine outcome rather than an exception. Track non-submissions alongside negative recommendations, because a drug that never enters the process leaves no decision record to find.